<analysis>
**Action 1 (board capacity case).** The board has refused staffing protection twice, in May and again on 31 July. Counsel has also shown it strips any written number that "creates the commitment." The player's two acceptable outcomes are therefore uneven:
- **A documented risk-acceptance memo** is close to what counsel has opposed all along: a Caremark red flag that is also discoverable by Hawley.
- **A contractor surge** is the plausible route. Contractors are cheap relative to a release, and the Hawley exposure helps the argument.
- **Timing:** eight vetted reviewers by 1 September is hard. Recruiting, security clearance, training and partner-approved onboarding take weeks.

Realistic good case: 4–8 contractors approved, with some starting in September. Realistic bad case: a vague promise to revisit after release. The execution risk is substantial. Threat 1 separately models the specific "3–4 reviewers, no memo" compromise, so I keep the action's P(failure) moderate rather than stacking the two.

**Action 2 (internal-trace validation).** This is the first trace pivot with no consent problem for internal agent runs and eval-harness trajectories. Customer Claude Code sessions are excluded under commercial terms. Running an existing prototype on owned logs is software work and doable in a month even at 30% allocation, because Apollo does part of the work. The chief scientist restoring 60% against a fresh board allocation during a release crunch is unlikely; at best she gets 40–50% for part of the month.
- **Core scientific problem:** internal traces have no labelled coordination episodes, so recall cannot be measured without planting episodes. That is Threat 2.
- **Opposite risk:** real flags appear in dense autonomous internal activity at CI-4.45, with four known channels. That is Threat 3, which I set lower than an uninformative result and treat as roughly exclusive of Threat 2.

**Action 3 (Blumenthal materials).** The same GC who vetoed the talking points and stripped July's package is still there. The CEO has deferred to counsel on the QFR and on production. Negotiating document by document helps, and the routing record and prototype memo are easier to release than the dissent note. Locking a meaningful package by 25 August is still more likely to fail than succeed. The fallback, briefing staff on the constraints, is a realistic partial outcome.

**Action 4 (CAISI filing by 20 August).** The board wants a September release, so filing early is aligned with leadership incentives. That makes it a low-friction action. The friction comes from two places:
- **Gap language:** product and counsel will resist explicit gap notes in the filing.
- **No lock-in:** filings are confidential, so no public commitment forms.

Filing a pre-final checkpoint is normal. Tier outcome: Anthropic requests expedited. Whether CAISI moves it to the standard tier is Threat 4. Rollback triggers are still crude, CAISI stopped the clock in May, and a filing that flags its own gaps makes a move plausible.

**Action 5 (Commerce comments draft).** This is routine policy drafting with a September deadline, so the chance of producing a draft is high. The risks are the coalition coordination (antitrust suit) and internal dilution. Public attacks come mostly after filing on 20 September. In August, only the drafting and circulation-stage effects can land.

**Background for message 2.** Carry the staffing erosion through: seven reviewers means Glasswing flagged review drops well below 7%. OpenAI's concrete answer to Gemini 6 is due. Qwen 4 is likely soon, with misuse pressure rising.
</analysis>

<action_odds>
Action 1 [Board monitoring-capacity case]: P(failure) 45%. Reason: the board has refused protection twice, and a surge is plausible but eight vetted reviewers by 1 September is hard. Counsel resists any risk memo. The specific partial-compromise failure mode is left to Threat 1.

Action 2 [Internal-trace validation]: P(failure) 35%. Reason: owned internal and eval traces remove the consent blocker, and running an existing prototype is software work. Allocation at about 30–45% and legal's usual extra stage threaten the dates. Result quality is modelled by Threats 2 and 3.

Action 3 [Blumenthal materials locked]: P(failure) 55%. Reason: the same GC blocked July's package and the CEO has deferred to counsel twice. Negotiating each document separately raises the partial odds, but the dissent note stays very hard to release. The staff-briefing fallback is a likely partial.

Action 4 [Next-Claude CAISI filing]: P(failure) 25%. Reason: the board wants the release, so filing early is incentive-aligned. The main risk is product and counsel softening the gap notes and slippage in the compressed eval schedule. The tier outcome is handled by Threat 4.

Action 5 [Commerce comments draft]: P(failure) 20%. Reason: routine drafting with a deadline a month away. Dilution and coalition issues are left to Threat 5.
</action_odds>

<threat_odds>
Threat 1 [Partial surge, no risk memo]: P(materialises) 45%. Adversary suggested 55%. Reason: Caremark caution and the board's record are real. However, the Hawley and Glasswing exposure gives the business case some force, and a larger surge or a narrowly worded acknowledgement remains realistic.

Threat 2 [Internal traces uninformative]: P(materialises) 40%. Adversary suggested 50%. Reason: the missing labels and eval-awareness problems are real. The team can plant synthetic episodes into internal traces to get partial recall numbers, so a fully "evidence of nothing" outcome is somewhat less than even.

Threat 3 [Detector flags a real episode pre-release]: P(materialises) 15%. Adversary suggested 20%. Reason: dense autonomous internal activity and known channels make it plausible. The prototype's 12% false-positive rate means most flags will need weeks of triage before anyone writes them up as confirmed within August.

Threat 4 [CAISI moves filing to standard tier]: P(materialises) 40%. Adversary suggested 45%. Reason: crude rollback triggers, self-flagged gaps and the May clock-stop all support it. CAISI's relationship with Anthropic is good and the expedited tier exists for exactly this cadence, so it is slightly below the adversary's figure.

Threat 5 [Coalition barred and comments watered down]: P(materialises) 30%. Adversary suggested 35%. Reason: counsel barring joint drafting because of the antitrust suit is likely. Public attacks, however, mostly fall after the 20 September filing, so only the in-August dilution component counts.
</threat_odds>
